| scholarly article | Q13442814 |
| P50 | author | Theoharis C Theoharides | Q90012323 |
| P2093 | author name string | Smaro Panagiotidou | |
| Irwin J Russell | |||
| Irene Tsilioni | |||
| Julia M Stewart | |||
| Rae M Gleason | |||
| Lauren Arbetman | |||
| P2860 | cites work | Oxycodone for neuropathic pain and fibromyalgia in adults | Q24193845 |
| Gabapentin for chronic neuropathic pain and fibromyalgia in adults | Q24194998 | ||
| Duloxetine for treating painful neuropathy, chronic pain or fibromyalgia | Q24201220 | ||
| The science of fibromyalgia | Q24609662 | ||
| Diagnostic and therapeutic potentials of exosomes in CNS diseases | Q38259010 | ||
| Qigong and fibromyalgia: randomized controlled trials and beyond | Q38283548 | ||
| An open-label pilot study of a formulation containing the anti-inflammatory flavonoid luteolin and its effects on behavior in children with autism spectrum disorders | Q38451268 | ||
| Mast Cells, Mastocytosis, and Related Disorders | Q38543985 | ||
| A randomized, double-blind, placebo-controlled, phase III trial of pregabalin in the treatment of patients with fibromyalgia. | Q39323653 | ||
| Human mast cells express corticotropin-releasing hormone (CRH) receptors and CRH leads to selective secretion of vascular endothelial growth factor | Q40412140 | ||
| Luteolin inhibits myelin basic protein-induced human mast cell activation and mast cell-dependent stimulation of Jurkat T cells | Q41139248 | ||
| Estrogen increases the severity of anaphylaxis in female mice through enhanced endothelial nitric oxide synthase expression and nitric oxide production | Q41566603 | ||
| Abnormal overexpression of mastocytes in skin biopsies of fibromyalgia patients | Q43080831 | ||
| Prevalence of fibromyalgia: a survey in five European countries | Q43407868 | ||
| Neutral endopeptidase terminates substance P-induced inflammation in allergic contact dermatitis | Q43516365 | ||
| The role of interleukin (IL)-17 in anxiety and depression of patients with rheumatoid arthritis | Q43757311 | ||
| Confirmation of an association between fibromyalgia and serotonin transporter promoter region (5- HTTLPR) polymorphism, and relationship to anxiety-related personality traits | Q43937890 | ||
| Corticotropin-releasing hormone and brain mast cells regulate blood-brain-barrier permeability induced by acute stress | Q44220866 | ||
| Gulf War veterans' health: medical evaluation of a U.S. cohort | Q44354600 | ||
| Chronic urticaria is usually associated with fibromyalgia syndrome | Q44445713 | ||
| Plasma nitrite levels, total antioxidant status, total oxidant status, and oxidative stress index in patients with tension-type headache and fibromyalgia | Q44619472 | ||
| A randomized, double-blind, placebo-controlled trial of duloxetine in the treatment of women with fibromyalgia with or without major depressive disorder | Q44841613 | ||
| Basal circadian and pulsatile ACTH and cortisol secretion in patients with fibromyalgia and/or chronic fatigue syndrome | Q44906295 | ||
| Culture, science and the changing nature of fibromyalgia | Q45817582 | ||
| DRD3 Ser9Gly polymorphism is related to thermal pain perception and modulation in chronic widespread pain patients and healthy controls. | Q45999045 | ||
| Increased levels of IL-17A in patients with fibromyalgia | Q46112669 | ||
| May genetic factors in fibromyalgia help to identify patients with differentially altered frequencies of immune cells? | Q46225786 | ||
| Plasma cytokine fluctuations over time in healthy controls and patients with fibromyalgia | Q46419008 | ||
| Pregabalin for the treatment of fibromyalgia syndrome: results of a randomized, double-blind, placebo-controlled trial | Q46428489 | ||
| High plasma levels of MCP-1 and eotaxin provide evidence for an immunological basis of fibromyalgia | Q46555325 | ||
| A 14-week, randomized, double-blinded, placebo-controlled monotherapy trial of pregabalin in patients with fibromyalgia | Q46559003 | ||
| Efficacy and safety of duloxetine for treatment of fibromyalgia in patients with or without major depressive disorder: Results from a 6-month, randomized, double-blind, placebo-controlled, fixed-dose trial | Q46659138 | ||
| Advances in fibromyalgia: possible role for central neurochemicals | Q47613091 | ||
| Synergistic effect of 5-hydroxytryptamine 3 and neurokinin 1 receptor antagonism in rodent models of somatic and visceral pain | Q48243650 | ||
| Dietary aspects in fibromyalgia patients: results of a survey on food awareness, allergies, and nutritional supplementation. | Q48288903 | ||
| The relationship between a common catechol-O-methyltransferase (COMT) polymorphism val(158) met and fibromyalgia | Q48367547 | ||
| Double-blind, multicenter trial comparing acetyl l-carnitine with placebo in the treatment of fibromyalgia patients. | Q48467122 | ||
| CD3+CD56+natural killer T cells in fibromyalgia syndrome patients: association with the intensity of depression | Q48489962 | ||
| Evidence for an association between an enhanced reactivity of interleukin-6 levels and reduced glucocorticoid sensitivity in patients with fibromyalgia | Q48839350 | ||
| Fibromyalgia: fibromyalgia-all in the brain? | Q49019961 | ||
| Oral coenzyme Q10 supplementation improves clinical symptoms and recovers pathologic alterations in blood mononuclear cells in a fibromyalgia patient. | Q50505146 | ||
| Cytokine patterns in fibromyalgia and their correlation with clinical manifestations. | Q50898803 | ||
| Altered subcellular localization of IL-33 leads to non-resolving lethal inflammation. | Q53283592 | ||
| Association of adrenergic receptor gene polymorphisms with different fibromyalgia syndrome domains. | Q54475400 | ||
| IL-33 is a mediator rather than a trigger of the acute allergic response in humans. | Q54637856 | ||
| Lower plasma Coenzyme Q10 in depression: a marker for treatment resistance and chronic fatigue in depression and a risk factor to cardiovascular disorder in that illness | Q56767123 | ||
| The role of IL-17-secreting mast cells in inflammatory joint disease | Q57667231 | ||
| Pregabalin Rectifies Aberrant Brain Chemistry, Connectivity, and Functional Response in Chronic Pain Patients | Q60691571 | ||
| Mast Cells as Sensors of Cell Injury through IL-33 Recognition | Q63257866 | ||
| Synergistic action of estradiol and myelin basic protein on mast cell secretion and brain myelin changes resembling early stages of demyelination | Q71610031 | ||
| Interleukin (IL)-10 inhibits nuclear factor kappa B (NF kappa B) activation in human monocytes. IL-10 and IL-4 suppress cytokine synthesis by different mechanisms | Q72167883 | ||
| Bladder mast cell expression of high affinity oestrogen receptors in patients with interstitial cystitis | Q72531466 | ||
| Possible association of fibromyalgia with a polymorphism in the serotonin transporter gene regulatory region | Q73165884 | ||
| The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society | Q74454469 | ||
| Association between Th-17 cytokine profile and clinical features in patients with spondyloarthritis | Q82276744 | ||
| Evidence of central inflammation in fibromyalgia-increased cerebrospinal fluid interleukin-8 levels | Q82729060 | ||
| Mast cells and inflammation | Q83029950 | ||
| Mast cells promote Th1 and Th17 responses by modulating dendritic cell maturation and function | Q83859246 | ||
| Serotonin-selective reuptake inhibitors and nonsteroidal anti-inflammatory drugs--important considerations of adverse interactions especially for the treatment of myalgic encephalomyelitis/chronic fatigue syndrome | Q84414993 | ||
| Pain management: Fibromyalgia drugs are 'as good as it gets' in chronic pain | Q84628785 | ||
| Inflammatory/stress feedback dysregulation in women with fibromyalgia | Q84984031 | ||
| Mast cells in fibromyalgia | Q85337976 | ||
| Atopic conditions in search of pathogenesis and therapy | Q86711018 | ||
| A questionnaire using the modified 2010 American College of Rheumatology criteria for fibromyalgia: specificity and sensitivity in clinical practice | Q87032015 | ||
| Serum prolidase enzyme activity and oxidative status in patients with fibromyalgia | Q87426750 | ||
| High serum corticotropin-releasing hormone (CRH) and bone marrow mast cell CRH receptor expression in a mastocytosis patient | Q88198169 | ||
| Brain "fog," inflammation and obesity: key aspects of neuropsychiatric disorders improved by luteolin | Q26802187 | ||
| Targeting IL-33 in autoimmunity and inflammation | Q28081990 | ||
| Distinct plasma immune signatures in ME/CFS are present early in the course of illness | Q28263550 | ||
| Effects of luteolin, quercetin and baicalein on immunoglobulin E-mediated mediator release from human cultured mast cells | Q28373264 | ||
| Oxidative stress correlates with headache symptoms in fibromyalgia: coenzyme Q₁₀ effect on clinical improvement | Q28482427 | ||
| Stimulated human mast cells secrete mitochondrial components that have autocrine and paracrine inflammatory actions | Q28484407 | ||
| Oxidative stress stimulates IL-4 and IL-6 production in mast cells by an APE/Ref-1-dependent pathway | Q28576813 | ||
| The effects of plant flavonoids on mammalian cells: implications for inflammation, heart disease, and cancer | Q29617123 | ||
| The many roles of chemokines and chemokine receptors in inflammation | Q29618880 | ||
| IL-17 and TNF-α sustain neutrophil recruitment during inflammation through synergistic effects on endothelial activation | Q30515381 | ||
| Alarmins: awaiting a clinical response | Q30523797 | ||
| A critical review of the data related to the safety of quercetin and lack of evidence of in vivo toxicity, including lack of genotoxic/carcinogenic properties | Q31121766 | ||
| Intramuscular injection of hrRANTES causes mast cell recruitment and increased transcription of histidine decarboxylase in mice: lack of effects in genetically mast cell-deficient W/WV mice. | Q31962390 | ||
| Sexual abuse and lifetime diagnosis of somatic disorders: a systematic review and meta-analysis | Q33157671 | ||
| Treatment of fibromyalgia syndrome with antidepressants: a meta-analysis | Q33399660 | ||
| Efficacy of multicomponent treatment in fibromyalgia syndrome: a meta-analysis of randomized controlled clinical trials | Q33403803 | ||
| Treatment of fibromyalgia syndrome with gabapentin and pregabalin--a meta-analysis of randomized controlled trials | Q33470807 | ||
| Efficacy of cognitive-behavioral therapies in fibromyalgia syndrome - a systematic review and metaanalysis of randomized controlled trials | Q33648680 | ||
| IL-33 augments substance P-induced VEGF secretion from human mast cells and is increased in psoriatic skin | Q33732911 | ||
| Comparative efficacy and acceptability of amitriptyline, duloxetine and milnacipran in fibromyalgia syndrome: a systematic review with meta-analysis | Q33747253 | ||
| Mast cells enhance T cell activation: Importance of mast cell-derived TNF. | Q33772139 | ||
| Preliminary Evidence of Increased Pain and Elevated Cytokines in Fibromyalgia Patients with Defective Growth Hormone Response to Exercise | Q33844288 | ||
| Increased concentrations of nerve growth factor in cerebrospinal fluid of patients with fibromyalgia | Q33868079 | ||
| Abnormal sensitization and temporal summation of second pain (wind-up) in patients with fibromyalgia syndrome. | Q33937161 | ||
| Neurophysiologic evidence for a central sensitization in patients with fibromyalgia | Q33966038 | ||
| Accelerated brain gray matter loss in fibromyalgia patients: premature aging of the brain? | Q34003523 | ||
| Systematic review with meta-analysis: cytokines in fibromyalgia syndrome. | Q34060700 | ||
| Mitochondrial uncoupling protein 2 inhibits mast cell activation and reduces histamine content | Q34077923 | ||
| Brain imaging in fibromyalgia syndrome | Q34127256 | ||
| Central sensitization: Implications for the diagnosis and treatment of pain | Q34144741 | ||
| Mast cell activation and autism | Q34156983 | ||
| Effects of bedtime very low dose cyclobenzaprine on symptoms and sleep physiology in patients with fibromyalgia syndrome: a double-blind randomized placebo-controlled study | Q34212757 | ||
| Large candidate gene association study reveals genetic risk factors and therapeutic targets for fibromyalgia. | Q34214963 | ||
| Mast cells: versatile gatekeepers of pain | Q34225889 | ||
| The effects of dietary flavonoids on the regulation of redox inflammatory networks. | Q34278356 | ||
| Cognitive behavioral therapy for fibromyalgia | Q36577533 | ||
| Spinal interleukin-17 promotes thermal hyperalgesia and NMDA NR1 phosphorylation in an inflammatory pain rat model. | Q36584981 | ||
| The development of allergic inflammation | Q36613696 | ||
| Corticotropin-releasing hormone and the blood-brain-barrier | Q36664658 | ||
| The genetics of fibromyalgia syndrome | Q36691781 | ||
| Complementary and alternative exercise for fibromyalgia: a meta-analysis | Q36739178 | ||
| The fibromyalgia family study: a genome-wide linkage scan study | Q36745449 | ||
| Cerebrospinal fluid corticotropin-releasing factor concentration is associated with pain but not fatigue symptoms in patients with fibromyalgia | Q36796597 | ||
| Differential release of mast cell mediators and the pathogenesis of inflammation | Q36819882 | ||
| A meta-analysis of the efficacy of fibromyalgia treatment according to level of care | Q36955370 | ||
| Fibromyalgia syndrome: approach to management. | Q37103601 | ||
| Etiology of fibromyalgia: the possible role of infection and vaccination | Q37244861 | ||
| New insights on mast cell activation via the high affinity receptor for IgE | Q37260865 | ||
| A symptom-based approach to pharmacologic management of fibromyalgia | Q37428736 | ||
| Neurophysiopathogenesis of fibromyalgia syndrome: a unified hypothesis | Q37568752 | ||
| Alternative medical interventions used in the treatment and management of myalgic encephalomyelitis/chronic fatigue syndrome and fibromyalgia | Q37700757 | ||
| Pathophysiology and antioxidant status of patients with fibromyalgia | Q37727078 | ||
| Flavonoids and the CNS. | Q37839688 | ||
| Fibromyalgia: from pathophysiology to therapy | Q37902512 | ||
| Brain-derived neurotrophic factor and exercise in fibromyalgia syndrome patients: a mini review | Q37972548 | ||
| Fibromyalgia: mechanisms and potential impact of the ACR 2010 classification criteria | Q37978128 | ||
| The use of flavonoids in central nervous system disorders. | Q38120019 | ||
| A focus on mast cells and pain | Q38152516 | ||
| Nerve growth factor and nociception: from experimental embryology to new analgesic therapy. | Q38199415 | ||
| Exosomes in neurologic and psychiatric disorders | Q38218899 | ||
| Catechol O-methyltransferase haplotype predicts immediate musculoskeletal neck pain and psychological symptoms after motor vehicle collision | Q34284528 | ||
| Is a subtype of autism an allergy of the brain? | Q34345620 | ||
| Management of fibromyalgia syndrome | Q34368422 | ||
| Fibromyalgia is associated with decreased connectivity between pain- and sensorimotor brain areas | Q34369980 | ||
| Fibromyalgia and cytokines | Q34400019 | ||
| Fibromyalgia: a clinical review | Q34415411 | ||
| Unique immunologic patterns in fibromyalgia | Q34514119 | ||
| Evaluation for safety of antioxidant chemopreventive agents | Q34563425 | ||
| Fibromyalgia and overlapping disorders: the unifying concept of central sensitivity syndromes | Q34577348 | ||
| TNF trafficking to human mast cell granules: mature chain-dependent endocytosis | Q34620371 | ||
| Fibromyalgia criteria and severity scales for clinical and epidemiological studies: a modification of the ACR Preliminary Diagnostic Criteria for Fibromyalgia | Q34626709 | ||
| COMT moderates the relation of daily maladaptive coping and pain in fibromyalgia | Q34645918 | ||
| Corticotropin-releasing hormone induces skin vascular permeability through a neurotensin-dependent process | Q34650833 | ||
| TGF-beta and IL-6 drive the production of IL-17 and IL-10 by T cells and restrain T(H)-17 cell-mediated pathology | Q34712326 | ||
| Evaluation and management of endocrine dysfunction in fibromyalgia | Q34746536 | ||
| Flavonoids: prospective drug candidates | Q34875200 | ||
| Fibromyalgia: anti-inflammatory and stress responses after acute moderate exercise | Q34984715 | ||
| Evaluation of the effectiveness of pregabalin in alleviating pain associated with fibromyalgia: using functional magnetic resonance imaging study | Q34989769 | ||
| Role for monocyte chemoattractant protein-1 in the induction of chronic muscle pain in the rat | Q35001326 | ||
| Luteolin inhibits human keratinocyte activation and decreases NF-κB induction that is increased in psoriatic skin | Q35109173 | ||
| Estrogen receptors regulate innate immune cells and signaling pathways | Q35236340 | ||
| The novel flavone tetramethoxyluteolin is a potent inhibitor of human mast cells | Q35305446 | ||
| Cytokine and chemokine profiles in fibromyalgia, rheumatoid arthritis and systemic lupus erythematosus: a potentially useful tool in differential diagnosis | Q35619740 | ||
| Mast cell-orchestrated immunity to pathogens | Q35747350 | ||
| Mast cells and autoimmunity | Q36010603 | ||
| Patients with fibromyalgia display less functional connectivity in the brain's pain inhibitory network | Q36116420 | ||
| Phenotypic and functional plasticity of cells of innate immunity: macrophages, mast cells and neutrophils | Q36141195 | ||
| Chemokines, chemokine receptors and pain | Q36229171 | ||
| Corticotropin-releasing hormone and extracellular mitochondria augment IgE-stimulated human mast-cell vascular endothelial growth factor release, which is inhibited by luteolin | Q36298946 | ||
| Clinical evidence for cervical myelopathy due to Chiari malformation and spinal stenosis in a non-randomized group of patients with the diagnosis of fibromyalgia | Q36333690 | ||
| Amitriptyline and prochlorperazine inhibit proinflammatory mediator release from human mast cells: possible relevance to chronic fatigue syndrome | Q36401159 | ||
| Fibromyalgia--new concepts of pathogenesis and treatment. | Q36434113 | ||
| Is inflammation a mitochondrial dysfunction-dependent event in fibromyalgia? | Q36562600 | ||
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | fibromyalgia | Q540571 |
| P304 | page(s) | 255-263 | |
| P577 | publication date | 2015-08-25 | |
| P1433 | published in | Journal of Pharmacology and Experimental Therapeutics | Q1500272 |
| P1476 | title | Fibromyalgia syndrome in need of effective treatments | |
| P478 | volume | 355 |
| Q61806277 | Acupuncture therapy for fibromyalgia: a systematic review and meta-analysis of randomized controlled trials |
| Q54437951 | Comparative efficacy and tolerability of duloxetine, pregabalin, and milnacipran for the treatment of fibromyalgia: a Bayesian network meta-analysis of randomized controlled trials. |
| Q90037920 | Diagnostic and therapeutic challenge - fibromyalgia |
| Q91012541 | Effects of attachment-based compassion therapy (ABCT) on brain-derived neurotrophic factor and low-grade inflammation among fibromyalgia patients: A randomized controlled trial |
| Q58086570 | Effects of imidazoline I2 receptor agonists on reserpine-induced hyperalgesia and depressive-like behavior in rats |
| Q38753091 | Fibromyalgia Pathogenesis and Treatment Options Update |
| Q37581692 | Functional MRI of the Reserpine-Induced Putative Rat Model of Fibromyalgia Reveals Discriminatory Patterns of Functional Augmentation to Acute Nociceptive Stimuli |
| Q92711498 | Mast Cells, Neuroinflammation and Pain in Fibromyalgia Syndrome |
| Q88105624 | Neurogenic inflammation in fibromyalgia |
| Q36618726 | Neuropeptides CRH, SP, HK-1, and Inflammatory Cytokines IL-6 and TNF Are Increased in Serum of Patients with Fibromyalgia Syndrome, Implicating Mast Cells |
| Q64271958 | Psychological impact of fibromyalgia: current perspectives |
| Q92447847 | Recent advances in our understanding of mast cell activation - or should it be mast cell mediator disorders? |
| Q38881756 | Recent strategies for drug development in fibromyalgia syndrome |
| Q59136726 | Saffron () versus duloxetine for treatment of patients with fibromyalgia: A randomized double-blind clinical trial |
| Q89498881 | Serum Vascular Endothelial Growth Factor and Vascular Endothelial Growth Factor Receptor-1 Levels in Patients With Fibromyalgia Syndrome |
| Q36936629 | Serum cortisol and dehydroepiandrosterone-sulfate levels after balneotherapy and physical therapy in patients with fibromyalgia |
| Q97681448 | Serum proteome profiles revealed dysregulated proteins and mechanisms associated with fibromyalgia syndrome in women |
| Q30840941 | Signs of ongoing inflammation in female patients with chronic widespread pain: A multivariate, explorative, cross-sectional study of blood samples |
| Q89697737 | T Cell Subpopulations in the Physiopathology of Fibromyalgia: Evidence and Perspectives |
| Q92651353 | Types of pain and their psychosocial impact in women with rheumatoid arthritis |
Search more.